Hummingbird Diagnostics GmbH (Hummingbird) is a provider of clinical research and testing services. It develops miRNA-based liquid biopsy diagnostics that find application in early detection of disease indications. The company discovers, validates, and analyzes genomic biomarkers especially derived from body fluid samples. It offers multilevel biomarker services and solutions. Hummingbird’s services comprise DNA and RNA extraction services, validation of biomarker candidates and quantitative analysis, microarray services and bioinformatic services, among others. Its products find applications in the treatment of cancer, chronic inflammatory diseases, cardiovascular diseases, and infectious disease. The company caters to pharmaceutical, biotech industry and academic life science customers. Hummingbird is headquartered in Heidelberg, Baden-Wuerttemberg, Germany.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Hummingbird Diagnostics GmbH
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Hummingbird Diagnostics GmbH Company Overview
Hummingbird Diagnostics GmbH Company Snapshot
Hummingbird Diagnostics GmbH Pipeline Products and Ongoing Clinical Trials Overview
Companion Diagnostic Test - Bladder Cancer Product Overview
Diagnostic Test - Acute Myocardial Infarction
Diagnostic Test - Acute Myocardial Infarction Product Overview
Diagnostic Test - Alzheimer's Disease
Diagnostic Test - Alzheimer's Disease Product Overview
Diagnostic Test - Breast Cancer
Diagnostic Test - Breast Cancer Product Overview
Diagnostic Test - Cancer Panel
Diagnostic Test - Cancer Panel Product Overview
Diagnostic Test - Heart Failure
Diagnostic Test - Heart Failure Product Overview
Diagnostic Test - IBD
Diagnostic Test - IBD Product Overview
Diagnostic Test - Melanoma
Diagnostic Test - Melanoma Product Overview
Diagnostic Test - Multiple Sclerosis
Diagnostic Test - Multiple Sclerosis Product Overview
Diagnostic Test - NSCLC
Diagnostic Test - NSCLC Product Overview
Diagnostic Test - Parkinson's Disease
Diagnostic Test - Parkinson's Disease Product Overview
miLung Blood Test
miLung Blood Test Product Overview
miLung Blood Test Clinical Trial
Hummingbird Diagnostics GmbH - Key Competitors
Hummingbird Diagnostics GmbH - Key Employees
Hummingbird Diagnostics GmbH - Locations And Subsidiaries
Head Office
Recent Developments
Hummingbird Diagnostics GmbH, Recent Developments
Jan 23, 2024: Hummingbird Diagnostics Announces Initiation of Patient Recruitment for Clinical Study Evaluating miLungDx as a Novel Diagnostic Test for Early-stage Lung Cancer
Oct 25, 2023: Hummingbird Diagnostics to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference
Jul 11, 2023: Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology
May 31, 2023: Hummingbird Diagnostics to present poster on miLung small RNA-Based Blood Test at the ASCO 2023 Annual Meeting
Jun 23, 2022: Hummingbird Diagnostics publishes study of miRisk as a predictor of immunotherapy efficacy in advanced-stage NSCLC
Mar 31, 2022: Hummingbird Diagnostics announces publication of study on the utility of miRisk, a blood-based microRNA analysis, to predict overall survival for advanced non-small cell lung cancer in npj Precision Oncology
Apr 22, 2020: SkylineDx launches melanoma test in United States to support cancer care
Dec 14, 2015: Validation of Blood-based MiRNAs for Early Diagnosis of Lung Cancer
Table 14: Diagnostic Test - Alzheimer's Disease - Product Status
Table 15: Diagnostic Test - Alzheimer's Disease - Product Description
Table 16: Diagnostic Test - Breast Cancer - Product Status
Table 17: Diagnostic Test - Breast Cancer - Product Description
Table 18: Diagnostic Test - Cancer Panel - Product Status
Table 19: Diagnostic Test - Cancer Panel - Product Description
Table 20: Diagnostic Test - Heart Failure - Product Status
Table 21: Diagnostic Test - Heart Failure - Product Description
Table 22: Diagnostic Test - IBD - Product Status
Table 23: Diagnostic Test - IBD - Product Description
Table 24: Diagnostic Test - Melanoma - Product Status
Table 25: Diagnostic Test - Melanoma - Product Description
Table 26: Diagnostic Test - Multiple Sclerosis - Product Status
Table 27: Diagnostic Test - Multiple Sclerosis - Product Description
Table 28: Diagnostic Test - NSCLC - Product Status
Table 29: Diagnostic Test - NSCLC - Product Description
Table 30: Diagnostic Test - Parkinson's Disease - Product Status
Table 31: Diagnostic Test - Parkinson's Disease - Product Description
Table 32: miLung Blood Test - Product Status
Table 33: miLung Blood Test - Product Description
Table 34: miLung Blood Test - Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung Early Detection of Lung Cancer Based on Small RNA Signatures - Boston II